Publication
International arbitration report
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Author:
Canada | Publication | August 20, 2020
We advised you that the COVID-19 deadlines were extended to August 24, 2020, and this was the last extension.
However, the Canadian Intellectual Property Office (CIPO) has just indicated that ALL electronic filing systems at CIPO will be UNAVAILABLE from the period starting Friday, August 21 at 7 p.m. EDT and ending on Sunday, August 23 at 11:59 p.m. EDT – that is, the weekend before the August 24 deadline.
Therefore, in view of this last-minute change CIPO has added an additional week to the last COVID deadline extension until August 31, 2020.
http://www.ic.gc.ca/eic/site/cipointernet-internetopic.nsf/eng/wr04767.html
Presumably, all CIPO electronic systems will be available from August 24, 2020, to August 31, 2020, for last-minute submissions under the COVID-19 deadline extension.
Given this further development, we once again highly recommend that applicants and owners of Canadian IP should carefully review their portfolios to ensure any actions that have been delayed in view of these extensions are now promptly attended to before August 31.
In this regard, as a convergence of filings on August 31 might strain the CIPO electronic filing systems, kindly resolve any outstanding deadlines as soon as possible.
Publication
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023